A Phase 3, global, multicenter, randomized, open-label study comparing sacituzumab govitecan with the standard of care (SOC) in participants with previously treated extensive-stage small cell lung cancer (ES-SCLC).
Contact Information for Access
Status
ATTIVO
Objective of the study
The objectives of the study are to compare the efficacy of the drug Sacituzumab Govitecan with the standard of care and to evaluate whether it results in longer survival compared to the standard of care.
Pulmonary microcytoma.
ClinicalTrials.gov ID NCT06801834
Sponsor: Gilead Sciences
Medication
Sacituzumab Govitecan (antibody-drug conjugate - Trop2)
Topotecan (topoisomerase I inhibitor)
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with small cell lung cancer (SCLC) who have previously received 1 or 2 lines of therapy.
View the full study Back to search page